NCT01005407 - Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine | Biotech Hunter

Enrollment

2,452

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

May 31, 2011

Conditions

Healthy

Interventions

BIOLOGICAL

HEPLISAV and/or Placebo

Intramuscular (IM) injections on Week 0 and Week 4; placebo (saline) injection at Week 24

BIOLOGICAL

Engerix-B

Intramuscular (IM) injections on Week 0, Week 4 and Week 24

Trial Locations (32)

Unknown

Huntsville

San Diego

Santa Ana

Denver

Melbourne

Pinellas Park

Atlanta

Chicago

Peoria

South Bend

Rockville

Brooklyn Center

Edina

Kansas City

St Louis

Rochester

Cincinnati

Erie

Grove City

Jefferson Hills

Pittsburgh

Upper Saint Clair

Anderson

Greer

Nashville

Dallas

Katy

San Antonio

Norfolk

Mount Pearl

Toronto

Montreal